The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
Year: 2016
Type: article
Study design: Clinical Trial
Source: The Lancet Haematology
Institutions: University of Leeds, Mid Yorkshire Hospitals NHS Trust, Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Barts Health NHS Trust, Sheffield Teaching Hospitals NHS Foundation Trust, University College Hospital, The Christie Hospital, The Christie NHS Foundation Trust, Plymouth Hospital, University Hospitals Plymouth NHS Trust, University Hospitals Bristol NHS Foundation Trust, Heart of England NHS Foundation Trust, Gloucestershire Hospitals NHS Foundation Trust, Glan Clwyd Hospital, Leeds Teaching Hospitals NHS Trust, University of Birmingham, Queen's University Belfast
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: relapsed multiple myeloma, salvage autologous stem cell transplantation, overall survival, high-dose melphalan, oral cyclophosphamide, bortezomib, doxorubicin, dexamethasone, reinduction chemotherapy, second remission, progression-free survival, time to progression, treatment toxicity, quality of life
Open Access status: green
OpenAlex ID: W2465647135
